Tevogen Bio Holdings (TVGN)
NASDAQ:TVGN
Want to see TVGN full AI Analyst Report?
Top Page
Tevogen Bio Holdings
(NASDAQ:TVGN)
Select Model
Select Model
Rating:44Neutral
Price Target:
$6.00
▲(1775.00% Upside)
Action:ReiteratedDate:04/10/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses and cash burn, and negative equity). Technicals also remain bearish with negative MACD and price below key longer-term moving averages. Valuation is difficult to justify on earnings due to losses, while recent corporate actions modestly reduce listing risk but do not offset the underlying financial pressure.
Positive Factors
Nasdaq listing compliance regained
Regaining Nasdaq compliance via the reverse split materially reduces near-term delisting risk and preserves access to a regulated trading venue. That sustained listing status supports future capital-raising options and market visibility, which are durable enablers for financing clinical development.
Negative Factors
No commercial revenue
Absence of product revenue over multiple years indicates the company remains pre‑commercial and wholly reliant on external financing. Without demonstrated sales or commercialization, future cash needs and execution risk remain elevated, making operational and funding sustainability uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Nasdaq listing compliance regained
Regaining Nasdaq compliance via the reverse split materially reduces near-term delisting risk and preserves access to a regulated trading venue. That sustained listing status supports future capital-raising options and market visibility, which are durable enablers for financing clinical development.
Read all positive factors
Tevogen Bio Holdings (TVGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$26.82M
Dividend YieldN/A
Average Volume (3M)557.82K
Price to Earnings (P/E)―
Beta (1Y)1.00
Revenue GrowthN/A
EPS Growth-234.46%
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.50
Shares Outstanding4,164,205
10 Day Avg. Volume531,944
30 Day Avg. Volume557,817
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-6.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market Cap1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-57.67
Enterprise Value/Ebitda-1.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-9.5
Revenue Forecast (FY)N/A
Tevogen Bio Holdings Business Overview & Revenue Model
Company Description
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed t...
How the Company Makes Money
null...
Tevogen Bio Holdings Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
16
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -509.20K | -403.58K | -378.36K | 0.00 | 0.00 |
| EBITDA | -25.63M | -13.14M | -58.89M | 4.41M | -14.99M |
| Net Income | -26.28M | -10.11M | -60.48M | 4.41M | -15.60M |
Balance Sheet | |||||
| Total Assets | 4.38M | 3.46M | 5.51M | 7.74M | 7.66M |
| Cash, Cash Equivalents and Short-Term Investments | 552.37K | 1.28M | 1.05M | 5.48M | 7.12M |
| Total Debt | 3.10M | 2.89M | 95.42M | 40.01M | 23.48M |
| Total Liabilities | 12.62M | 10.14M | 99.93M | 41.69M | 24.15M |
| Stockholders Equity | -8.23M | -6.67M | -94.43M | -33.95M | -16.49M |
Cash Flow | |||||
| Free Cash Flow | -12.39M | -12.00M | -8.30M | -9.13M | -5.38M |
| Operating Cash Flow | -12.33M | -12.00M | -8.17M | -8.66M | -5.27M |
| Investing Cash Flow | -64.44K | 0.00 | -133.00K | -479.04K | -109.73K |
| Financing Cash Flow | 11.66M | 12.23M | 3.87M | 7.50M | 12.50M |
Tevogen Bio Holdings Technical Analysis
Negative
0.32
Price Trends
8.92
Negative
13.90
Negative
28.38
Negative
Market Momentum
-0.77
Negative
49.45
Neutral
86.29
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TVGN, the sentiment is Negative. The current price of 0.32 is below the 20-day moving average (MA) of 5.20, below the 50-day MA of 8.92, and below the 200-day MA of 28.38, indicating a neutral trend. The MACD of -0.77 indicates Negative momentum. The RSI at 49.45 is Neutral, neither overbought nor oversold. The STOCH value of 86.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TVGN.
Tevogen Bio Holdings Risk Analysis
Tevogen Bio Holdings disclosed 76 risk factors in its most recent earnings report. Tevogen Bio Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tevogen Bio Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $282.00M | -1.51 | -53.83% | ― | -10.57% | 1.98% | |
52 Neutral | $225.18M | -6.23 | -131.80% | ― | ― | -16.26% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $513.12M | -7.52 | -65.03% | ― | -84.46% | 33.32% | |
44 Neutral | $26.82M | -2.09 | 389.21% | ― | ― | -234.46% | |
44 Neutral | $172.52M | -1.32 | -30.02% | ― | ― | 25.84% |
* Healthcare Sector Average
TVGN
Tevogen Bio Holdings
6.44
-44.56
-87.37%
NKTX
Nkarta
2.42
0.67
38.29%
CCCC
C4 Therapeutics
2.89
1.79
162.73%
STTK
Shattuck Labs
7.17
6.41
843.42%
NVCT
Nuvectis Pharma
8.50
-0.20
-2.30%
ACTU
Actuate Therapeutics, Inc.
2.15
-6.08
-73.88%
Tevogen Bio Holdings Corporate Events
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Tevogen Bio Regains Nasdaq Compliance After Reverse Split
Positive
Mar 25, 2026
Tevogen Bio Holdings Inc. announced that on March 20, 2026, it received notice from Nasdaq that the company had regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market, resolving a prior listing...
Regulatory Filings and ComplianceStock Split
Tevogen Bio Announces 1-for-50 Reverse Stock Split
Neutral
Mar 4, 2026
On March 3, 2026, Tevogen Bio Holdings Inc. filed a Certificate of Amendment in Delaware to implement a 1-for-50 reverse stock split of its common stock, effective March 6, 2026, following shareholder approval on February 19, 2026. The move will r...
Business Operations and StrategyShareholder MeetingsStock Split
Tevogen Bio Shareholders Approve Reverse Split Authorization
Positive
Feb 25, 2026
On February 19, 2026, Tevogen Bio Holdings Inc. held a special meeting of stockholders at which investors voted on amending the company’s 2024 equity incentive plan and authorizing a reverse stock split at a ratio between 1-for-25 and 1-for-...
Business Operations and StrategyDividends
Tevogen Bio Explores Potential One-Time Special Cash Dividend
Neutral
Jan 30, 2026
On January 30, 2026, Tevogen Bio Holdings announced that its Board of Directors plans to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent on the company achieving future financial milestones such a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.